NitroMed (NTMD) Announces BiDil Data to be Presented at Heart Failure Society of America

September 13, 2007 7:35 AM EDT

NitroMed, Inc. (NASDAQ: NTMD) said that five abstracts will be presented at the 11th Annual Scientific Meeting of the Heart Failure Society of America taking place September 16-19, 2007 in Washington, DC.

"This new information helps broaden our clinical understanding of BiDil by adding to the body of evidence that BiDil represents important adjunct therapy in the treatment of black heart failure patients. These latest data about BiDil's efficacy to improve survival in high risk heart failure patients with atrial fibrillation, its use in the elderly, its use with concomitant therapies, and the genetic results, expand our understanding of BiDil's effects in younger and aging patients with different concomitant diseases and heart failure medications," said Manuel Worcel, MD, NitroMed's Chief Medical Officer.

NitroMed of Lexington, Massachusetts is an emerging pharmaceutical company and the maker of BiDil(R) (isosorbide dinitrate/hydralazine hydrochloride), an orally administered medicine available in the United States for the treatment of heart failure in self-identified black patients.

Related Categories

Corporate News

Stocks Mentioned

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?